{"id":"ipv-at-6-and-fipv-at-22-weeks-rotarix","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Irritability or fussiness"},{"rate":"5-10","effect":"Diarrhea (Rotarix)"},{"rate":"2-5","effect":"Vomiting (Rotarix)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPV contains chemically inactivated poliovirus that triggers humoral and cellular immunity without causing disease. Rotarix is a live attenuated rotavirus vaccine that replicates in the intestinal tract, inducing mucosal and systemic immune responses. Together, these vaccines prevent poliomyelitis and rotavirus gastroenteritis through antibody production and T-cell mediated immunity.","oneSentence":"IPV (inactivated poliovirus vaccine) and fIPV (fractional dose IPV) stimulate immune responses against poliovirus types 1, 2, and 3, while Rotarix protects against rotavirus infection through live attenuated viral immunization.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:11.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis (poliovirus types 1, 2, and 3)"},{"name":"Prevention of rotavirus gastroenteritis"}]},"trialDetails":[{"nctId":"NCT02847026","phase":"PHASE4","title":"Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-09","conditions":"Poliomyelitis","enrollment":1144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IPV at 6 and fIPV at 22 weeks, Rotarix","genericName":"IPV at 6 and fIPV at 22 weeks, Rotarix","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"IPV (inactivated poliovirus vaccine) and fIPV (fractional dose IPV) stimulate immune responses against poliovirus types 1, 2, and 3, while Rotarix protects against rotavirus infection through live attenuated viral immunization. Used for Prevention of poliomyelitis (poliovirus types 1, 2, and 3), Prevention of rotavirus gastroenteritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}